Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LYN | P07948 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 6/20 | 0.38 |
| ▸ | CCND1 | P24385 | 6/20 | 0.38 |
| ▸ | CCND2 | P30279 | 2/20 | 0.38 |
| ▸ | CCND3 | P30281 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16285680 | 0.90 | BTK (0.55) | LYNSRCBTKKDM1ACDK4 | |
| SCHEMBL16286148 | 0.87 | PTK2 (0.42) | LYNSRCBTKKDM1ACDK4 | |
| SCHEMBL16285663 | 0.85 | CDK4 (0.42) | KDM1ACDK4CCND1CCND2CCND3 | |
| SCHEMBL16286147 | 0.79 | BTK (0.50) | LYNSRCBTKCDK4CCND1 | |
| SCHEMBL16285672 | 0.75 | CCND3 (0.47) | BTKKDM1ACDK4CCND1CCND2 | |
| SCHEMBL16285695 | 0.73 | OPRL1 (0.42) | CDK4CCND1LMNASOS1CCNA2 | |
| SCHEMBL16285685 | 0.73 | FYN (0.47) | BTKKDM1AHTR7CDK4CCND1 | |
| SCHEMBL16286112 | 0.72 | PTK2 (0.45) | KDM1ACDK4CCND1CCND2CCND3 | |
| SCHEMBL10192792 | 0.71 | CDK4 (0.51) | CDK4CCND1CCND2CCND3CCNA2 | |
| SCHEMBL16309191 | 0.69 | JAK2 (0.49) | CDK4CCND1CCND2CCND3CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | LYN 1996/4885SRC 966/4885BTK 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.